Prognostic values of various hematological variables as markers of systemic inflammation in metastatic lung cancer

Basit Öğe Kaydı
dc.authorscopusid57219020945
dc.authorscopusid6701472672
dc.authorscopusid8666331800
dc.contributor.authorBayir, Duygu
dc.contributor.authorSeber, Selçuk
dc.contributor.authorYetişyiğit, Tarkan
dc.date.accessioned2022-05-11T14:39:59Z
dc.date.available2022-05-11T14:39:59Z
dc.date.issued2020
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractBackground: Chronic state of inflammation is an important factor in advanced cancer which is used by tumor cells for maintaining survival and growth. Hematological parameters such as neutrophil/lymphocyte ratio (NLR), thrombocyte/lymphocyte ratio (TLR), and lymphocyte/monocyte ratio (LMR) are reliable indicators of systemic inflammation. We aimed to elucidate the effect of hematological parameters and clinical features of patients on the prognosis of advanced-stage non-small cell lung cancer (NSCLC). Methods: We included 102 Stage IV NSCLC patients who presented to the oncology clinic between 2010 and 2016. Pretreatment clinical parameters and NLR, TLR, and LMR were retrieved from the medical records. The cutoff values, calculated with receiver operating curve analysis, for NLR, LMR, and TLR were 2.5, 3, and 183, respectively. All patients were divided into two groups according to cutoff values and analyzed accordingly. Results: Median overall survival and progression-free survival were 10 and 6 months, respectively. In univariate analysis, high NLR, high TLR, and low LMR were found to be significantly associated with survival. Among clinical parameters having eastern cooperative oncology group performance score 0-1, older age (>= 70 years) single metastatic disease was prognostic. In multivariate Cox regression analysis, only the number of metastatic lesions and LMR were found to be independent predictors for survival. Conclusion: Among hematological parameters, only LMR was found to be an independent predictor of survival in patients with advanced-stage NSCLC.
dc.identifier.doi10.4103/jcrt.JCRT_397_17
dc.identifier.endpage736
dc.identifier.issn0973-1482
dc.identifier.issn1998-4138
dc.identifier.issue4en_US
dc.identifier.pmid32930111
dc.identifier.scopus2-s2.0-85091053647
dc.identifier.scopusqualityQ3
dc.identifier.startpage731
dc.identifier.urihttps://doi.org/10.4103/jcrt.JCRT_397_17
dc.identifier.urihttps://hdl.handle.net/20.500.11776/8820
dc.identifier.volume16
dc.identifier.wosWOS:000585412200006
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorBayir, Duygu
dc.institutionauthorSeber, Selçuk
dc.institutionauthorYetişyiğit, Tarkan
dc.language.isoen
dc.publisherWolters Kluwer Medknow Publications
dc.relation.ispartofJournal of Cancer Research and Therapeutics
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAdvanced stage
dc.subjectlymphocyte-monocyte ratio
dc.subjectnon-small cell lung cancer
dc.subjectLymphocyte Ratio
dc.subjectNeutrophil
dc.titlePrognostic values of various hematological variables as markers of systemic inflammation in metastatic lung cancer
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu